Skip to main content
Top
Published in: BMC Nephrology 1/2023

Open Access 01-12-2023 | Acute Kidney Injury | Research

Continuous venovenous hemodiafiltration versus standard medical therapy for the prevention of rhabdomyolysis-induced acute kidney injury: a retrospective cohort study

Authors: Yan Meng, Ming-xue Zhou, Chun-bo Wu, De-hua Wang, Jian-rong Zhao, Dong-yin Shi

Published in: BMC Nephrology | Issue 1/2023

Login to get access

Abstract

Aim

To determine whether continuous venovenous hemodiafiltration (CVVHDF) plus standard medical therapy (SMT) vs. SMT alone prevents rhabdomyolysis (RM)-induced acute kidney injury (AKI) and analyze the related health economics.

Methods

This retrospective cohort study involved 9 RM patients without AKI, coronary heart disease, or chronic kidney disease treated with CVVHDF plus SMT (CVVHDF + SMT group). Nine matched RM patients without AKI treated with SMT only served as controls (SMT group). Baseline characteristics, biochemical indexes, renal survival data, and health economic data were compared between groups. In the CVVHDF + SMT group, biochemical data were compared at different time points.

Results

At 2 and 7 days after admission, serum biochemical indices (e.g., myoglobin, creatine kinase, creatinine, and blood urea nitrogen) did not differ between the groups. Total (P = 0.011) and daily hospitalization costs (P = 0.002) were higher in the CVVHDF + SMT group than in the SMT group. After 53 months of follow-up, no patient developed increased serum creatinine, except for 1 CVVHDF + SMT-group patient who died of acute myocardial infarction. In the CVVHDF + SMT group, myoglobin levels significantly differed before and after the first CVVHDF treatment (P = 0.008), and serum myoglobin, serum creatinine, and blood urea nitrogen decreased significantly at different time points after CVVHDF.

Conclusions

Although CVVHDF facilitated myoglobin elimination, its addition to SMT did not improve biochemical indices like serum myoglobin, serum creatine kinase, creatinine, blood urea nitrogen, and lactate dehydrogenase or the long-term renal prognosis. Despite similar hospitalization durations, both total and daily hospitalization costs were higher in the CVVHDF + SMT group.
Literature
1.
go back to reference Chavez LO, Leon M, Einav S, et al. Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice. Crit Care. 2016;20(1):1–11.CrossRef Chavez LO, Leon M, Einav S, et al. Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice. Crit Care. 2016;20(1):1–11.CrossRef
2.
go back to reference Cabral BMI, Edding SN, Portocarrero JP, et al. Rhabdomyolysis Dis. Mon. 2020;66(8):1–18. Cabral BMI, Edding SN, Portocarrero JP, et al. Rhabdomyolysis Dis. Mon. 2020;66(8):1–18.
3.
go back to reference Huerta-Alardín A, Varon J, Marik PE. Bench-to-bedside review: rhabdomyolysis – an overview for clinicians. Crit Care. 2005;9(2):158–69.CrossRefPubMed Huerta-Alardín A, Varon J, Marik PE. Bench-to-bedside review: rhabdomyolysis – an overview for clinicians. Crit Care. 2005;9(2):158–69.CrossRefPubMed
4.
go back to reference Delaney KA, Givens ML, Vohra RB. Use of RIFLE criteria to predict the severity and prognosis of acute kidney injury in emergency department patients with rhabdomyolysis. J Emerg Med. 2012;42(5):521–8.CrossRefPubMed Delaney KA, Givens ML, Vohra RB. Use of RIFLE criteria to predict the severity and prognosis of acute kidney injury in emergency department patients with rhabdomyolysis. J Emerg Med. 2012;42(5):521–8.CrossRefPubMed
5.
go back to reference Chatzizisis YS, Misirli G, Hatzitolios AI, et al. The syndrome of rhabdomyolysis: complications and treatment. Eur J Intern Med. 2008;19(8):568–74.CrossRefPubMed Chatzizisis YS, Misirli G, Hatzitolios AI, et al. The syndrome of rhabdomyolysis: complications and treatment. Eur J Intern Med. 2008;19(8):568–74.CrossRefPubMed
6.
go back to reference Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med. 2009;361(14):62–72.CrossRefPubMed Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med. 2009;361(14):62–72.CrossRefPubMed
7.
8.
go back to reference Naka T, Jones D, Baldwin I, et al. Myoglobin clearance by super high-flux hemofiltration in a case of severe rhabdomyolysis: a case report. Crit Care. 2005;9(2):R90–95.CrossRefPubMedPubMedCentral Naka T, Jones D, Baldwin I, et al. Myoglobin clearance by super high-flux hemofiltration in a case of severe rhabdomyolysis: a case report. Crit Care. 2005;9(2):R90–95.CrossRefPubMedPubMedCentral
9.
go back to reference Premru V, Kovač J, Buturović-Ponikvar J, et al. High cut-off membrane hemodiafiltration in myoglobinuric acute renal failure: a case series. Ther Apher Dial. 2011;15(3):287–91.CrossRefPubMed Premru V, Kovač J, Buturović-Ponikvar J, et al. High cut-off membrane hemodiafiltration in myoglobinuric acute renal failure: a case series. Ther Apher Dial. 2011;15(3):287–91.CrossRefPubMed
10.
go back to reference Ankur G, Peter T, Krishnam RP, et al. Rhabdomyolysis: Revisit Ulster Med J. 2021;90(2):61–9. Ankur G, Peter T, Krishnam RP, et al. Rhabdomyolysis: Revisit Ulster Med J. 2021;90(2):61–9.
11.
go back to reference Torres PA, Helmstetter JA, Kaye AM, et al. Rhabdomyolysis: pathogenesis, diagnosis, and treatment. Ochsner J. 2015;15(1):58–69.PubMedPubMedCentral Torres PA, Helmstetter JA, Kaye AM, et al. Rhabdomyolysis: pathogenesis, diagnosis, and treatment. Ochsner J. 2015;15(1):58–69.PubMedPubMedCentral
12.
go back to reference Kidney Disease Improving Global Outcomes (KDIGO). Acute kidney Injury Work Group: KDIGO clinical practice guideline for acute kidney injury. Kidney Int Supplement. 2012;2(1):1–138. Kidney Disease Improving Global Outcomes (KDIGO). Acute kidney Injury Work Group: KDIGO clinical practice guideline for acute kidney injury. Kidney Int Supplement. 2012;2(1):1–138.
13.
go back to reference Jens M, Joakim C, Lisbeth L, et al. Prevention of rhabdomyolysis-induced acute kidney injury – A DASAIM/DSIT clinical practice guideline. Acta Anaesthesiol Scand. 2019;63(5):576–86.CrossRef Jens M, Joakim C, Lisbeth L, et al. Prevention of rhabdomyolysis-induced acute kidney injury – A DASAIM/DSIT clinical practice guideline. Acta Anaesthesiol Scand. 2019;63(5):576–86.CrossRef
14.
15.
go back to reference Sorrentino SA, Kielstein JT, Lukasz A, et al. High permeability dialysis membrane allows effective removal of myoglobin in acute kidney injury resulting from rhabdomyolysis. Crit Care Med. 2011;39(1):184–6.CrossRefPubMed Sorrentino SA, Kielstein JT, Lukasz A, et al. High permeability dialysis membrane allows effective removal of myoglobin in acute kidney injury resulting from rhabdomyolysis. Crit Care Med. 2011;39(1):184–6.CrossRefPubMed
16.
go back to reference Naka T, Jones D, Baldwin I, et al. Myoglobin clearance by super high-flux hemofiltration in a case of severe rhabdomyolysis: a case report. Crit Care. 2005;9(2):1–6.CrossRef Naka T, Jones D, Baldwin I, et al. Myoglobin clearance by super high-flux hemofiltration in a case of severe rhabdomyolysis: a case report. Crit Care. 2005;9(2):1–6.CrossRef
17.
go back to reference Premru V, Kova J, Buturovi-Ponikvar J, et al. High cut-off membrane hemodiafiltration in Myoglobinuric Acute Renal failure: a Case Series. Therapeutic Apheresis and Dialysis. 2011;15(3):287–91.CrossRefPubMed Premru V, Kova J, Buturovi-Ponikvar J, et al. High cut-off membrane hemodiafiltration in Myoglobinuric Acute Renal failure: a Case Series. Therapeutic Apheresis and Dialysis. 2011;15(3):287–91.CrossRefPubMed
18.
go back to reference Peltonen S, Åhlström A, Kylävainio V, et al. The effect of combining intermittent hemodiafiltration with forced alkaline diuresis on plasma myoglobin in rhabdomyolysis. Acta Anaesthesiol Scand. 2010;51(5):553–8.CrossRef Peltonen S, Åhlström A, Kylävainio V, et al. The effect of combining intermittent hemodiafiltration with forced alkaline diuresis on plasma myoglobin in rhabdomyolysis. Acta Anaesthesiol Scand. 2010;51(5):553–8.CrossRef
19.
go back to reference Cruz DN, Bagshaw SM. Does continuous renal replacement therapy have a role in the treatment of rhabdomyolysis complicated by acute kidney injury? Semin Dial. 2011;24(4):417–20.CrossRefPubMed Cruz DN, Bagshaw SM. Does continuous renal replacement therapy have a role in the treatment of rhabdomyolysis complicated by acute kidney injury? Semin Dial. 2011;24(4):417–20.CrossRefPubMed
20.
go back to reference Zeng X, Zhang L, Wu T, et al. Continuous renal replacement therapy (CRRT) for rhabdomyolysis. Cochrane Database Syst Rev. 2014;15(6):1–40. Zeng X, Zhang L, Wu T, et al. Continuous renal replacement therapy (CRRT) for rhabdomyolysis. Cochrane Database Syst Rev. 2014;15(6):1–40.
21.
go back to reference Cornelissen JJ, Haanstra W, Haarman HJ, et al. Plasma exchange in rhabdomyolysis. Intensive Care Med. 1989;15(8):528–9.CrossRefPubMed Cornelissen JJ, Haanstra W, Haarman HJ, et al. Plasma exchange in rhabdomyolysis. Intensive Care Med. 1989;15(8):528–9.CrossRefPubMed
23.
go back to reference Maccario M, Fumagalli C, Dottori V, et al. The association between rhabdomyolysis and acute renal failure in patients undergoing cardiopulmonary bypass. J Cardiovasc Surg (Torino). 1996;37(2):153–9.PubMed Maccario M, Fumagalli C, Dottori V, et al. The association between rhabdomyolysis and acute renal failure in patients undergoing cardiopulmonary bypass. J Cardiovasc Surg (Torino). 1996;37(2):153–9.PubMed
24.
go back to reference Szpirt WM. Plasmapheresis is not justified in treatment of rhabdomyolysis and acute renal failure. J Cardiovasc Surg (Torino). 1997;38(5):557.PubMed Szpirt WM. Plasmapheresis is not justified in treatment of rhabdomyolysis and acute renal failure. J Cardiovasc Surg (Torino). 1997;38(5):557.PubMed
25.
go back to reference Tang W, Chen Z, Wu W, et al. Renal protective effects of early continuous venovenous hemofiltration in rhabdomyolysis: improved renal mitochondrial dysfunction and inhibited apoptosis. Artif Organs. 2013;37(4):390–400.CrossRefPubMed Tang W, Chen Z, Wu W, et al. Renal protective effects of early continuous venovenous hemofiltration in rhabdomyolysis: improved renal mitochondrial dysfunction and inhibited apoptosis. Artif Organs. 2013;37(4):390–400.CrossRefPubMed
Metadata
Title
Continuous venovenous hemodiafiltration versus standard medical therapy for the prevention of rhabdomyolysis-induced acute kidney injury: a retrospective cohort study
Authors
Yan Meng
Ming-xue Zhou
Chun-bo Wu
De-hua Wang
Jian-rong Zhao
Dong-yin Shi
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2023
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-023-03242-x

Other articles of this Issue 1/2023

BMC Nephrology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine